The HFSA Annual Scientific Meeting is happening NOW (Sept. 30-Oct. 3)!
2020 | HFSA

Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients with Heart Failure with Reduced Ejection Fraction

Practice News Research

In a recent study, researchers "estimated the effect of comprehensive disease-modifying pharmacological therapy against previously established conventional therapy (ACE inhibitor or ARB plus β blocker) using overall trial-level  estimates from pivotal randomised clinical trials that assessed the efficacy and safety of MRA,6 ARNI,9 and SGLT2 inhibitors." 

Researchers interpreted that "among patients with HFrEF, the anticipated aggregate treatment effects of early comprehensive disease-modifying pharmacological therapy are substantial and support the combination use of an ARNI, β blocker, MRA, and SGLT2 inhibitor as a new therapeutic standard."

Read the full study in The Lancet >>